PRTA Valuation

Prothena Corporation PLC

Add to Watchlist

Advanced Chart

6.810

-0.06(-0.873%)1D

Overview
Forecast
Valuation
Earnings

PRTA Relative Valuation

PRTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRTA is overvalued; if below, it's undervalued.

Historical Valuation

Prothena Corporation PLC (PRTA) is now in the Fair zone, suggesting that its current forward PS ratio of 14.28 is considered Fairly compared with the five-year average of -2.65. The fair price of Prothena Corporation PLC (PRTA) is between 6.31 to 35.69 according to relative valuation methord.

Relative Value

Fair Zone

6.31-35.69

Current Price：6.73

Fair

-1.68

Trailing

Forward

0.00

EV/EBITDA

Prothena Corporation PLC. (PRTA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -5.83. The thresholds are as follows: Strongly Undervalued below -51.82, Undervalued between -51.82 and -28.82, Fairly Valued between 17.17 and -28.82, Overvalued between 17.17 and 40.16, and Strongly Overvalued above 40.16. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.18

EV/EBIT

Prothena Corporation PLC. (PRTA) has a current EV/EBIT of 0.18. The 5-year average EV/EBIT is -1.19. The thresholds are as follows: Strongly Undervalued below -36.80, Undervalued between -36.80 and -19.00, Fairly Valued between 16.61 and -19.00, Overvalued between 16.61 and 34.41, and Strongly Overvalued above 34.41. The current Forward EV/EBIT of 0.18 falls within the Historic Trend Line -Fairly Valued range.

14.28

Prothena Corporation PLC. (PRTA) has a current PS of 14.28. The 5-year average PS is 82.41. The thresholds are as follows: Strongly Undervalued below -250.74, Undervalued between -250.74 and -84.17, Fairly Valued between 248.98 and -84.17, Overvalued between 248.98 and 415.56, and Strongly Overvalued above 415.56. The current Forward PS of 14.28 falls within the Historic Trend Line -Fairly Valued range.

-2.09

P/OCF

Prothena Corporation PLC. (PRTA) has a current P/OCF of -2.09. The 5-year average P/OCF is -8.56. The thresholds are as follows: Strongly Undervalued below -121.10, Undervalued between -121.10 and -64.83, Fairly Valued between 47.72 and -64.83, Overvalued between 47.72 and 103.99, and Strongly Overvalued above 103.99. The current Forward P/OCF of -2.09 falls within the Historic Trend Line -Fairly Valued range.

-2.66

P/FCF

Prothena Corporation PLC. (PRTA) has a current P/FCF of -2.66. The 5-year average P/FCF is 11.31. The thresholds are as follows: Strongly Undervalued below -341.20, Undervalued between -341.20 and -164.94, Fairly Valued between 187.57 and -164.94, Overvalued between 187.57 and 363.83, and Strongly Overvalued above 363.83. The current Forward P/FCF of -2.66 falls within the Historic Trend Line -Fairly Valued range.

Prothena Corporation PLC (PRTA) has a current Price-to-Book (P/B) ratio of 0.85. Compared to its 3-year average P/B ratio of 3.32 , the current P/B ratio is approximately -74.52% higher. Relative to its 5-year average P/B ratio of 3.82, the current P/B ratio is about -77.84% higher. Prothena Corporation PLC (PRTA) has a Forward Free Cash Flow (FCF) yield of approximately -35.01%. Compared to its 3-year average FCF yield of -10.88%, the current FCF yield is approximately 221.80% lower. Relative to its 5-year average FCF yield of -7.97% , the current FCF yield is about 339.03% lower.

0.85

P/B

Median3y

3.32

Median5y

3.82

-35.01

FCF Yield

Median3y

-10.88

Median5y

-7.97

Competitors Valuation Multiple

The average P/S ratio for PRTA's competitors is 29.38, providing a benchmark for relative valuation. Prothena Corporation PLC Corp (PRTA) exhibits a P/S ratio of 14.28, which is -51.41% above the industry average. Given its robust revenue growth of 5556.00%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PRTA.O

Prothena Corporation PLC

Monte Rosa Therapeutics Inc

Cartesian Therapeutics Inc

Foghorn Therapeutics Inc

Candel Therapeutics Inc

Loss

338.16M

Performance Decomposition

Market capitalization of PRTA decreased by 69.15% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 50.00K to 2.83M.

The secondary factor is the Margin Expansion, contributed -98.53%to the performance.

Overall, the performance of PRTA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

5556.00%

50.00K → 2.83M

Revenue Growth

-98.53%

-144.48K → -2.13K

Margin Expansion

-5526.62%

0.06 → -3.36

P/E Change

-69.15%